BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) infections remain a significant cause of morbidity and mortality. We experienced an increased incidence of MRSA surgical-site infections (MRSA SSIs) at our institution. However, to our knowledge, no studies have evaluated the risk factors and outcomes of MRSA SSIs in cancer patients. METHODS: We conducted a case-control study and identified all patients who had developed MRSA SSIs at our institution from July 1, 2002 to July 30, 2003, and all patients who had undergone surgery by the same surgical team during the same time period but who had not developed MRSA SSIs. Cases and controls were age-matched at 1:2 ratio. RESULTS: The study included 29 cases and 58 controls. Mean interval between surgery and MRSA SSI onset was 17.8 days (range 3-75 days). Cases were more likely than controls to have progressive cancer (72 versus 38%), have received antibiotics (mainly quinolones) within 24 h of surgery (17 versus 2%), have had ongoing infection (10 versus 0%), and have had longer hospital and intensive care unit stays (11.0 versus 7.8 days and 3.4 versus 1.5 days) (all P < 0.05). In a multivariate logistic regression analysis, significant predictors of MRSA SSI in cancer patients were antibiotics use <24 h of surgery and progressive cancer. No surgical factors (i.e., procedure time or timing of perioperative antibiotics) were associated with increased risk of MRSA SSI. CONCLUSIONS: Several clinical and postoperative factors were associated with increased risk of MRSA SSI in cancer patients, but antibiotic use before surgery (especially quinolones) and progressive cancer were the only independent predictors.
BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) infections remain a significant cause of morbidity and mortality. We experienced an increased incidence of MRSA surgical-site infections (MRSA SSIs) at our institution. However, to our knowledge, no studies have evaluated the risk factors and outcomes of MRSA SSIs in cancerpatients. METHODS: We conducted a case-control study and identified all patients who had developed MRSA SSIs at our institution from July 1, 2002 to July 30, 2003, and all patients who had undergone surgery by the same surgical team during the same time period but who had not developed MRSA SSIs. Cases and controls were age-matched at 1:2 ratio. RESULTS: The study included 29 cases and 58 controls. Mean interval between surgery and MRSA SSI onset was 17.8 days (range 3-75 days). Cases were more likely than controls to have progressive cancer (72 versus 38%), have received antibiotics (mainly quinolones) within 24 h of surgery (17 versus 2%), have had ongoing infection (10 versus 0%), and have had longer hospital and intensive care unit stays (11.0 versus 7.8 days and 3.4 versus 1.5 days) (all P < 0.05). In a multivariate logistic regression analysis, significant predictors of MRSA SSI in cancerpatients were antibiotics use <24 h of surgery and progressive cancer. No surgical factors (i.e., procedure time or timing of perioperative antibiotics) were associated with increased risk of MRSA SSI. CONCLUSIONS: Several clinical and postoperative factors were associated with increased risk of MRSA SSI in cancerpatients, but antibiotic use before surgery (especially quinolones) and progressive cancer were the only independent predictors.
Authors: Gill Norman; Ross A Atkinson; Tanya A Smith; Ceri Rowlands; Amber D Rithalia; Emma J Crosbie; Jo C Dumville Journal: Cochrane Database Syst Rev Date: 2017-10-30
Authors: Sminil N Mahajan; Jharna N Shah; Ray Hachem; Frank Tverdek; Javier A Adachi; Victor Mulanovich; Kenneth V Rolston; Issam I Raad; Roy F Chemaly Journal: Oncologist Date: 2012-06-15
Authors: Ashok Srinivasan; Steven E Seifried; Liang Zhu; Deo K Srivastava; Rosalie Perkins; Jerry L Shenep; Matthew J Bankowski; Randall T Hayden Journal: Pediatr Blood Cancer Date: 2010-09-09 Impact factor: 3.167
Authors: Fatemeh Askarian; Satoshi Uchiyama; J Andrés Valderrama; Clement Ajayi; Johanna U E Sollid; Nina M van Sorge; Victor Nizet; Jos A G van Strijp; Mona Johannessen Journal: Infect Immun Date: 2016-12-29 Impact factor: 3.441
Authors: Ellen Korol; Karissa Johnston; Nathalie Waser; Frangiscos Sifakis; Hasan S Jafri; Mathew Lo; Moe H Kyaw Journal: PLoS One Date: 2013-12-18 Impact factor: 3.240